Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Advanced Development of Filovirus and Lassa Fever Vaccines

by Global Biodefense Staff
March 13, 2016

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking proposals for advanced development of multivalent vaccines against Ebola virus, Sudan virus, Marburg virus and Lassa fever.

The effort also seeks to support technical advances in vaccine development for these filoviruses and Lassa virus.

The research and development activities supported through this BAA will allow candidate vaccines to progress through the product development pipeline toward licensure by the FDA.

Activities funded under this Broad Agency Announcement (BAA) funding mechanism may include:

  • Regulatory, clinical, non-clinical, and manufacturing product planning activities
  • Manufacturing and formulation process development
  • Manufacturing, characterization and release of pilot lot and cGMP material
  • Real time and accelerated vaccine stability testing
  • Conduct of non-clinical studies, including all IND-enabling toxicology studies, combination product approvals and multivalent immunogenicity and interference studies, as needed
  • Development, qualification and validation of all necessary assays and reagents
  • Design, conduct, and completion of a Phase 1 or Phase 2 clinical trials
  • Provision of sufficient clinical and non-clinical samples from all studies to NIAID

It is anticipated that multiple cost reimbursement, completion type contracts will be awarded for a five-year period of performance beginning on or about June 2, 2017. NIAID estimates that the average annual total cost (direct and indirect costs combined) is $10.8 million for all awards made under this effort.

The BAA is planned for official release on March 24. Further details are available via Solicitation Number: BAANIHAI2016064.

Tags: BAAEbolaLassa FeverMarburgNIHVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC